Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.
Reginster JY, Abadie E, Delmas P, Rizzoli R, Dere W, der Auwera P, Avouac B, Brandi ML, Daifotis A, Diez-Perez A, Calvo G, Johnell O, Kaufman JM, Kreutz G, Laslop A, Lekkerkerker F, Mitlak B, Nilsson P, Orloff J, Smillie M, Taylor A, Tsouderos Y, Ethgen D, Flamion B. Reginster JY, et al. Among authors: abadie e. Osteoporos Int. 2006 Jan;17(1):1-7. doi: 10.1007/s00198-005-1984-3. Epub 2005 Aug 10. Osteoporos Int. 2006. PMID: 16091835
The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis.
Delmas PD, Calvo G, Boers M, Abadie E, Avouac B, Kahan A, Kaufman JM, Laslop A, Lekkerkerker JF, Nilsson P, Van Zwieten-Boot B, Kreutz G, Reginster JY; Group for the Respect of Ethics and Excellence in Science (GREES). Delmas PD, et al. Among authors: abadie e. Osteoporos Int. 2002 Jan;13(1):1-5. doi: 10.1007/s198-002-8331-3. Osteoporos Int. 2002. PMID: 11878450 Review.
Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science.
Abadie EC, Devogealer JP, Ringe JD, Ethgen DJ, Bouvenot GM, Kreutz G, Laslop A, Orloff JJ, Vanderauwera PM, Delmas PD, Dere WH, Branco J, Altman RD, Avouac BP, Menkes CJ, Vanhaelst L, Mitlak BH, Tsouderos Y, Reginster JY. Abadie EC, et al. Semin Arthritis Rheum. 2005 Aug;35(1):1-4. doi: 10.1016/j.semarthrit.2005.03.006. Semin Arthritis Rheum. 2005. PMID: 16084217 Review.
Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA.
Smolen JS, Boers M, Abadie EC, Breedveld FC, Emery P, Bardin T, Goel N, Ethgen DJ, Avouac BP, Dere WH, Durez P, Matucci-Cerinic M, Flamion B, Laslop A, Lekkerkerker FJ, Miossec P, Mitlak BH, Ormarsdóttir S, Paolozzi L, Rao R, Reiter S, Tsouderos Y, Reginster JY; Group for Respect of Ethics and Excellence in Science (GREES). Smolen JS, et al. Curr Med Res Opin. 2011 Feb;27(2):315-25. doi: 10.1185/03007995.2010.542135. Epub 2010 Dec 9. Curr Med Res Opin. 2011. PMID: 21142618
Uncertain future of trials in osteoporosis.
Kanis JA, Oden A, Johnell O, Caulin F, Bone H, Alexandre JM, Abadie E, Lekkerkerker F. Kanis JA, et al. Among authors: abadie e. Osteoporos Int. 2002;13(6):443-9. doi: 10.1007/s001980200052. Osteoporos Int. 2002. PMID: 12107656 Review.
Background for studies on the treatment of male osteoporosis: state of the art.
Kaufman JM, Johnell O, Abadie E, Adami S, Audran M, Avouac B, Sedrine WB, Calvo G, Devogelaer JP, Fuchs V, Kreutz G, Nilsson P, Pols H, Ringe J, Van Haelst L, Reginster JY. Kaufman JM, et al. Among authors: abadie e. Ann Rheum Dis. 2000 Oct;59(10):765-72. doi: 10.1136/ard.59.10.765. Ann Rheum Dis. 2000. PMID: 11005775 Free PMC article. Review.
Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis.
Smolen JS, Boers M, Abadie EC, Breedveld FC, Emery P, Bardin T, Goel N, Ethgen DJ, Avouac BP, Durez P, Flamion B, Laslop A, Miossec P, Reiter S, Reginster JY; Task Force of the Group for the Respect of Ethics and Excellence in Science. Smolen JS, et al. Rheumatology (Oxford). 2011 Oct;50(10):1732-6. doi: 10.1093/rheumatology/keq413. Epub 2011 Jan 17. Rheumatology (Oxford). 2011. PMID: 21242246 No abstract available.
Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.
Abadie E, Ethgen D, Avouac B, Bouvenot G, Branco J, Bruyere O, Calvo G, Devogelaer JP, Dreiser RL, Herrero-Beaumont G, Kahan A, Kreutz G, Laslop A, Lemmel EM, Nuki G, Van De Putte L, Vanhaelst L, Reginster JY; Group for the Respect of Excellence and Ethics in Science. Abadie E, et al. Osteoarthritis Cartilage. 2004 Apr;12(4):263-8. doi: 10.1016/j.joca.2004.01.006. Osteoarthritis Cartilage. 2004. PMID: 15023377 Free article. Review.
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis.
Goldhahn J, Scheele WH, Mitlak BH, Abadie E, Aspenberg P, Augat P, Brandi ML, Burlet N, Chines A, Delmas PD, Dupin-Roger I, Ethgen D, Hanson B, Hartl F, Kanis JA, Kewalramani R, Laslop A, Marsh D, Ormarsdottir S, Rizzoli R, Santora A, Schmidmaier G, Wagener M, Reginster JY. Goldhahn J, et al. Among authors: abadie e. Bone. 2008 Aug;43(2):343-347. doi: 10.1016/j.bone.2008.04.017. Epub 2008 May 7. Bone. 2008. PMID: 18544475 Review.
123 results